Peter M. Gocze
University of Oklahoma Health Sciences Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter M. Gocze.
Oncology | 1994
Peter M. Gocze; Helmut W. Vahrson; Dale A. Freeman
In the present study we evaluated the clinical usefulness of the tumor antigens, squamous cell carcinoma antigen (SCC) and ovarian carcinoma antigen (CA 125), in populations of patients with benign and malignant cervical disease. SCC and CA 125 levels were determined in the serum of 59 patients with invasive carcinoma of the uterine cervix and in 21 patients with benign cervical diseases. Before treatment of cervical cancer, SCC levels were elevated in 63% of the patients with squamous cell cancer while all 5 patients with adenocarcinoma had normal levels. CA 125 levels were elevated in 21% of the patients with cervical squamous cell cancer and in 3 of the 5 cases of adenocarcinoma of the cervix. In patients with benign cervical diseases, only 1 had a positive SCC level and none were positive for CA 125. No correlation was found between SCC levels and histological differentiation or clinical stage. In positive patients, serial SCC determinations correlated with the clinical course in 72.2%. Increasing levels were always associated with progression and increased on average 3 months before there was clinical evidence for disease progression. It is concluded from these studies that SCC levels are a useful marker for cervical cancer progression and recurrence. Levels of CA 125 were more likely to be elevated in patients with adenocarcinoma than squamous cell carcinoma, but when elevated in these latter patients, it also tended to predict tumor recurrence.
Gynecological Endocrinology | 1999
Peter M. Gocze; I. Szabó; Zoltan Porpaczy; Dale A. Freeman
Screening drugs used in obstetrical practice for effects on steroid hormone synthesis revealed that phenobarbital inhibited progesterone synthesis in MA-10 Leydig tumor cells. The inhibition was apparently a drug class effect since it could be reproduced by other barbiturates. Barbiturate blockade was reversible and could be bypassed in the MA-10 cells by using 22-hydroxycholesterol. Human granulosa cell progesterone synthesis was also inhibited in a dose dependent fashion by phenobarbital, secobarbital and barbituric acid. Significant inhibition occurred in dose ranges that would be therapeutic for treating epilepsy. From these data we conclude that barbiturates block steroidogenesis by inhibiting cholesterol transport to the cholesterol side chain cleavage enzyme.
Cytometry | 1994
Peter M. Gocze; Dale A. Freeman
Endocrinology | 1992
Peter M. Gocze; Dale A. Freeman
Gynecologic Oncology | 1997
Peter M. Gocze; Wesley G. Beamer; Frank H. de Jong; Dale A. Freeman
Experimental Cell Research | 1993
Peter M. Gocze; Dale A. Freeman
Endocrinology | 1993
Dale A. Freeman; Peter M. Gocze; Zoltan Porpaczy
The Lancet | 1993
Peter M. Gocze; Zoltan Porpaczy; John A. Baron; Ingemar Persson
The Lancet | 1993
Peter M. Gocze; Zoltan Porpaczy; John A. Baron; Ingemar Persson
JAMA | 1993
Peter M. Gocze; Dale A. Freeman